New Molecule could Effectively Treat Chemotherapy-Induced Neuropathy

New Molecule could Effectively Treat Chemotherapy Induced Neuropathy

The molecule has a novel mode of action and it could be first treatment against this neurological complication, which does not have effective treatment currently.

Peripheral neuropathy is major disadvantage of certain chemotherapeutics used in the treatment of cancers. It is characterized by tingling, numbness, pain or alterations in the functionality of patients. Cancer patients have to go through this complication despite having a demonstrated negative impact on the quality of life, increasing care expenses, and preventing the complete and effective administration of the cytostatic treatment with the potential decrease of survival chances.

Researchers from Neuro-Oncology Unit of Bellvitge University Hospital – Catalan Institute of Oncology have reported that new molecule is capable of preventing progression of peripheral neuropathy induced by chemotherapy in cancer patients. It can significantly help in reducing symptoms of neuropathy in colon cancer.  Researchers at the HUB-ICO-IDIBELL Unit detected a new molecule developed by the Catalan laboratory Esteve as a candidate to prevent this adverse effect. “Through a public-private partnership, we have been able to design a Phase 2b clinical trial, which has allowed us to get a great deal of scientific information – effect on pain, pathophysiology – and draw conclusions as to the potential of the drug in the prevention of neuropathies during cytostatic treatment”, said explains Dr. Bruna, lead of the study.

According to Targeted Cancer Therapies Market report published by Coherent Market Insights, chemotherapy has adverse effects on cancer patients, which include neuropathy. In any case, improving pain control and reducing the occurrence of severe neuropathy is undoubtedly the most prominent benefit of the development of this novel drug. As a result of the study, it was observed that cancer patients who took new drug showed low symptoms of disorders regarding nerve dysfunction. “Given the usual pace of clinical trials and drug agencies following fast-track approval processes in severe or orphan pathologies, this new drug could potentially reach the market soon, since it would be the first available treatment to avoid this type of neuropathy. In addition, it has other medical uses as a non-opioid analgesic”, said Bruna.

The molecule has a novel mode of action and it could be first treatment against this neurological complication, which does not have effective treatment currently.
Peripheral neuropathy is major disadvantage of certain chemotherapeutics used in the treatment of cancers. It is characterized by tingling, numbness, pain or alterations in the functionality of patients. Cancer patients have to go through this complication despite having a demonstrated negative impact on the quality of life, increasing care expenses, and preventing the complete and effective administration of the cytostatic treatment with the potential decrease of survival chances.
Researchers from Neuro-Oncology Unit of Bellvitge University Hospital – Catalan Institute of Oncology have reported that new molecule is capable of preventing progression of peripheral neuropathy induced by chemotherapy in cancer patients. It can significantly help in reducing symptoms of neuropathy in colon cancer. Researchers at the HUB-ICO-IDIBELL Unit detected a new molecule developed by the Catalan laboratory Esteve as a candidate to prevent this adverse effect. “Through a public-private partnership, we have been able to design a Phase 2b clinical trial, which has allowed us to get a great deal of scientific information – effect on pain, pathophysiology – and draw conclusions as to the potential of the drug in the prevention of neuropathies during cytostatic treatment”, said explains Dr. Bruna, lead of the study.
According to Targeted Cancer Therapies Market report published by Coherent Market Insights, chemotherapy has adverse effects on cancer patients, which include neuropathy. In any case, improving pain control and reducing the occurrence of severe neuropathy is undoubtedly the most prominent benefit of the development of this novel drug. As a result of the study, it was observed that cancer patients who took new drug showed low symptoms of disorders regarding nerve dysfunction. “Given the usual pace of clinical trials and drug agencies following fast-track approval processes in severe or orphan pathologies, this new drug could potentially reach the market soon, since it would be the first available treatment to avoid this type of neuropathy. In addition, it has other medical uses as a non-opioid analgesic”, said Bruna.

You may be interested

Business

Tricks Used by Insurance Companies to Deny Legit Claims

media - December 10, 2018

Health insurance companies strategize in making more and more money by paying out as little as possible. Many times, they deny legitimate claims which are covered under…

New Study Suggests Typical Use of Sunscreens Offers Less Sun Protection
Business
Business

New Study Suggests Typical Use of Sunscreens Offers Less Sun Protection

Mohit Joshi - December 10, 2018

Researchers from King's College London revealed that use of sunscreen offers less than half the sun protection as users apply more thinly than manufacturers recommend. In a…

Tamoxifen Market: Segmented by Application and Geography Trends, Growth and Forecasts 2026
Healthcare
Healthcare

Tamoxifen Market: Segmented by Application and Geography Trends, Growth and Forecasts 2026

Albert R - December 10, 2018

Tamoxifen Market report is a research database spread across various pages with multiple tables and figures in it. The research covers a valuable source of perceptive information…

Most from this category